Methylprednisolone in systemic lupus erythematosus

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical manifestations.
• Pulse methylprednisolone is a potent corticosteroid used to manage severe SLE flares.
• Understanding treatment efficacy and safety is crucial for managing SLE patients.

Purpose of the Study:

• To evaluate the clinical response and outcomes of pulse methylprednisolone therapy in patients with SLE.
• To assess the incidence of infections and mortality associated with this treatment regimen.

Main Methods:

• A cohort of 39 patients with SLE received intravenous pulse methylprednisolone (10 mg/kg/day for 3 days).
• Patients were monitored for 0-24 weeks post-therapy.
• Outcomes assessed included clinical response in lupus nephritis and non-renal manifestations, infection rates, and mortality.

Main Results:

• A majority of patients showed clinical improvement: 63.0% with lupus nephritis and 58.3% with non-renal lupus.
• Infections occurred in 28.2% of patients, with a 63.6% mortality rate among those infected.
• Overall mortality was 38.5%, with early deaths attributed to disease activity and later deaths to infection.

Conclusions:

• Pulse methylprednisolone therapy appears beneficial for managing SLE manifestations.
• The risk of infection and associated mortality necessitates careful monitoring during and after treatment.
• Risk-benefit assessment is essential, considering both therapeutic efficacy and potential adverse events.